Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

Journal of Viral Hepatitis

Volumn 17, Issue 7, 2010, Pages 459-468

  Witthoeft, T ^a   Hueppe, D ^b   John, C ^c   Goelz, J ^d   Heyne, R ^e   Moeller, B ^e   Teuber, G ^f   Wollschlaeger, S ^g   Baumgarten, A ^h   Simon, K G ⁱ   Moog, G ^j   Dikopoulos, N ^k   Mauss, S ^l  

^a Private Gastroenterological Practice Stade   (Germany)

^b Center of Gastroenterology   (Germany)

^c Center of Gastroenterology   (Germany)

^d Practice Centre Kaiserdamm   (Germany)

^e Hepatology and Gastroenterology   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^h General Practice   (Germany)

ⁱ Centre of Gastroenterology   (Germany)

^j Centre of Gastroenterology   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l Ctr HIV and Hepatogastroenterology   (Germany)

more..

Author keywords

Chronic hepatitis; HCV; PCR; Pegylated interferon; Ribavirin; Sustained virological response; Viral load

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CARDIOVASCULAR AGENT; CHOLINESTERASE INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS LOAD; COMPARATIVE STUDY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953575515     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01255.x     Document Type: Article

References (41)

1. World Health Authority. Hepatitis C Fact Sheet. 2000. Available from http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed February 3, 2009.
2. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008 48 : 148-162.
3. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008 13 : 18880.
4. Swain M, Lai M, Shiffman ML et al. Sustained virologic response resulting from treatment with peginterferon alfa-2a alone or in combination with ribavirin is durable and constitutes a cure: an ongoing 5-year follow-up. Gastroenterology 2007 132 : 741A.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975-982.
6. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346-355.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958-965.
8. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. NIH Consens Statement 2002 19 : 1 46.
9. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147-1171.
10. Zeuzem S. Standardtherapie der akuten und chronischenHepatitis C. Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten 2004. Available from http://www.kompetenznetz-hepatitis.de/aerzteforum/ standardtherapie-hep-c-zeuzem.pdf. Accessed November 30, 2008.
11. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006 101 : 2360-2378.
12. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2000 22 : 607-610.
13. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061-1069.
14. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 132 : 103-112.
15. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003 23 (Suppl. 1) 23-28.
16. Bruno R, Sacchi P, Ciappina V et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004 9 : 491-497.
17. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004 24 (Suppl. 2) 25-31.
18. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005 43 : 425-433.
19. Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008 47 : 1453-1461.
20. Maynard M, Gagnieu MC, Pradat P, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 during pegylated-interferon/ribavirin combination therapy in HCV patients. J Hepatol 2007 46 : S234.
21. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008 15 : 475-481.
22. Rebetol (ribavirin) Summary of Product Characteristics. Available from http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=3237. Accessed January 23, 2009.
23. Copegus (ribavirin) Summary of Product Characteristics. Available from http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=11755. Accessed January 23, 2009.
24. Ascione A, Tartaqlione MT, Lampasi F et al. Peginterferon Alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naïve patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol 2008 48 : S370.
25. Hofmann WP, Bock H, Weber C et al. Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists. Z Gastroenterol 2006 44 : 25-31.
26. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343 : 1666-1672.
27. Pockros PJ, Carithers R, Desmond P et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004 99 : 1298-1305.
28. Witthöft T, Möller B, Wiedmann KH et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German Open Safety Trial. J Viral Hepat 2007 14 : 788-796.
29. Gheorghe L, Iacob S, Sporea I et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007 16 : 23-29.
30. Sagir A, Heintges T, Akyazi Z et al. Therapy outcome in patients with chronic hepatitis C: role of therapy supervision by expert hepatologists. J Viral Hepat 2007 14 : 633-638.
31. Thomson BJ, Kwong G, Ratib S et al. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat 2008 15 : 271-278.
32. De Kaita K, Wong S, Renner E, Minuk GY. Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. Can J Gastroenterol 2006 20 : 87-90.
33. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351 : 438-450.
34. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839-2848.
35. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004 140 : 370-381.
36. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008 49 : 634-651.
37. Bain VG, Lee SS, Peltekian K et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther 2008 28 : 43-50.
38. Hézode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 360 : 1839-1850.
39. Rumi MG, Aghemo A, Prati GM et al. Randomized study comparing Peginterferon-alfa2a plus Ribavirin and Peginterferon-alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology 2008 48 : Abstract 212.
40. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 361 : 580-593.
41. McCone J, Hu K, McHutchison JG et al. Sustained Virologic Response (SVR) and Predictors of Response in African American (AA) Patients in the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) Phase 3b Study. Hepatology 2008 48 : Abstract 268.